Evaluation of Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis in Southwest China.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
06
04
2022
accepted:
22
05
2023
revised:
07
07
2023
medline:
10
7
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
The purpose of this study was to determine the diagnostic efficacy of Xpert MTB/RIF assay for rapid diagnosis of Tuberculosis (TB) and detection of rifampicin (RIF) resistance in patients suspected of having EPTB, assessing it against traditional culture and drug susceptibility test (DST) by proportional method, and the ability to predict multidrug resistance TB by Xpert MTB/RIF assay. In this study, the Xpert MTB/RIF assay was applied to 1,614 extrapulmonary specimens. Compared with TB culture and Composite Reference Standard (CRS), the Xpert MTB/RIF assay had a high sensitivity and specificity for detection of EPTB. Depending on the culture method or CRS as the standard, sensitivity of the Xpert MTB/RIF assay for detection of MTB in pleural effusion, cerebrospinal fluid, thoracic drainage fluid and throat swabs specimens were lower than that of other specimens. According to the experimental results, we have reason to believe that Xpert MTB/RIF assay is a rapid and simple technique with high sensitivity and specificity for diagnosing EPTB and detecting drug resistance in variety of specimens. Xpert MTB/RIF assay combined with DST maybe identify more cases of multi-drug resistant tuberculosis (MDR-TB).
Identifiants
pubmed: 37363913
doi: 10.1371/journal.pntd.0011403
pii: PNTD-D-21-00495
pmc: PMC10328326
doi:
Substances chimiques
Rifampin
VJT6J7R4TR
Antibiotics, Antitubercular
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0011403Informations de copyright
Copyright: © 2023 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Lancet Infect Dis. 2020 Dec;20(12):1457-1469
pubmed: 32673595
Sci Rep. 2014 Jul 11;4:5658
pubmed: 25014250
Expert Rev Anti Infect Ther. 2011 Apr;9(4):457-69
pubmed: 21504402
Arch Pathol Lab Med. 2001 Jan;125(1):122-6
pubmed: 11151065
Trop Med Int Health. 2016 Mar;21(3):385-92
pubmed: 26671654
Lancet. 2016 Mar 19;387(10024):1211-26
pubmed: 26377143
J Infect. 2012 Jun;64(6):580-8
pubmed: 22381459
J Clin Microbiol. 2011 Jul;49(7):2540-5
pubmed: 21593262
J Clin Microbiol. 2011 Apr;49(4):1202-5
pubmed: 21270230
Bull World Health Organ. 1969;41(1):21-43
pubmed: 5309084
J Clin Microbiol. 2011 Dec;49(12):4138-41
pubmed: 21956978
J Clin Microbiol. 2014 Jun;52(6):1818-23
pubmed: 24622091
Eur Respir J. 2012 Aug;40(2):442-7
pubmed: 22241741
Eur Respir J. 2013 Nov;42(5):1427-9
pubmed: 23900990
Future Microbiol. 2011 Sep;6(9):1067-82
pubmed: 21958145
Int J Tuberc Lung Dis. 2013 Sep;17(9):1217-9
pubmed: 23827859
Eur Respir J. 2014 Aug;44(2):435-46
pubmed: 24696113
BMC Infect Dis. 2004 Feb 23;4:6
pubmed: 15102325